FDA
-
-
-
-
-
-
-
Pharvaris presents data on deucrictibant for hereditary angioedema treatment
-
-
-
-
-
-
-
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
-
-
-
-
-
-
-
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Pharvaris Outlines 2025 Strategic Priorities
-
-
-
-
-
-
-
Pharvaris Presents Data at the Bradykinin Symposium 2024
-
326,551 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

